[Fundamental and clinical studies on beta-lactamase inhibitors].
Cluvulanic acid and sulbactam have been widely used in Japan as beta-lactamase inhibitors, and we will soon have tazobactam, the third beta-lactamase inhibitor. It will be available in combination with piperacillin(1:4), and expected excellent clinical efficacy in various infection, caused by class A, class D and class C beta-lactamase producing bacteria, including ESBLs producing gram negatives. The clinical usefulness of tazobactam/piperacillin might be exceeded those of drugs which combined with cluvulanic acid and sulbactam. However, it dose not inhibit class B beta-lactamase and large amount of class C beta-lactamase. There are some reports of newer beta-lactamase inhibitors, which show much more strong activities against class C or even against class B beta-lactamase in fundamental studies. Continuous studies will be needed to these agent for the future clinical use.
Niki
Y
Y
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy; D019818:Clavulanic Acid / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D006801:Humans; D010397:Penicillanic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage; D013407:Sulbactam / Q000008:administration & dosage*; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam; D010878:Piperacillin